Aeglea BioTherapeutics Investor Presentation Deck
Our strategy is built on three validated approaches to
address unmet needs in IBD
BEST-IN-CLASS ANTIBODY
ENGINEERING
Y
HALF-LIFE EXTENSION TECHNOLOGIES
TO IMPROVE CONVENIENCE¹
RATIONAL THERAPEUTIC
COMBINATIONS
Y
COMBINATION TARGETING TO ENHANCE
REMISSION RATES²
PRECISION IMMUNOLOGY
APPROACHES
GENETIC AND BIOMARKER SELECTION
TO IDENTIFY MOST LIKELY
RESPONDERS³
Sources: ¹ Several half-life extended antibodies are in clinical development, with at least two commercially approved (Evusheld, Beyfortus), Rosario, M, et. al. (2017); 2JNJ VEGA Phase 2 study demonstrated
approximately additive efficacy with a TNFa and IL-23 combination (~47% clinical remission at week 12) versus monotherapies (25% and 24% remission rates, respectively, Feagan, B. G. et al. Lancet
Gastroenterol. Hepatol. 8, 307-320 (2023); ³Prometheus Biosciences demonstrated a ~13% increase in clinical remission rates in CDx+ patients versus all-comers, Prometheus corporate materials
SPYRE
6View entire presentation